Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure-Reference-Cited by-同舟云学术

Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure

Published:2006-12 Issue:6 Volume:68 Page:1257-1262
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Ray Michael E.,Levy Larry B.,Horwitz Eric M.,Kupelian Patrick A.,Martinez Alvaro A.,Michalski Jeff M.,Pisansky Thomas M.,Zelefsky Michael J.,Zietman Anthony L.,Kuban Deborah A.

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer;Critz;J Clin Oncol,1996

2. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer;Critz;Urology,1997

3. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer;Critz;Urology,1997

4. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy;Critz;J Urol,1999

5. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen;Crook;Cancer,1997

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients;BMC Urology;2022-11-15

2. Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control;Radiotherapy and Oncology;2021-01

3. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients;Radiotherapy and Oncology;2020-10

4. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials;International Journal of Radiation Oncology*Biology*Physics;2019-08

5. Surrogate endpoints in early prostate cancer research;Translational Andrology and Urology;2018-06